Takeda Pharmaceutical
TAK
281 hedge funds and large institutions have $1.06B invested in Takeda Pharmaceutical in 2022 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 70 increasing their positions, 99 reducing their positions, and 44 closing their positions.
144% more call options, than puts
Call options by funds: $39.2M | Put options by funds: $16.1M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
28% more capital invested
Capital invested by funds: $829M → $1.06B (+$232M)
25% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 44
2% more funds holding
Funds holding: 276 → 281 (+5)
0.26% more ownership
Funds ownership: 4.04% → 4.29% (+0.26%)
29% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 99
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$38.9M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$37.4M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$34.4M |
| 4 |
Millennium Management
New York
|
+$17.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$24.5M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$21M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$14.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$9.47M |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$6.11M |
TAK Hedge Fund Activity: Q4 2022 in Review
281 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q4 2022, worth a combined $1.06B — up 28% from $829M a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new TAK positions and 44 closed out — a net gain of 11 holders — while 70 added to existing stakes and 99 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $38.9M. The largest seller was Brandes Investment Partners, cutting an estimated $24.5M.
- 281 institutional investors held Takeda Pharmaceutical (TAK) as of Q4 2022, up from 276 in Q3 2022.
- Funds reported $1.06B of Takeda Pharmaceutical stock for Q4 2022, up 28% quarter-over-quarter.
- 55 funds opened new Takeda Pharmaceutical positions in Q4 2022 and 44 closed out, a net change of +11 holders.
- The largest Takeda Pharmaceutical buyer in Q4 2022 was Point72 Asset Management, an estimated $38.9M added.
- The largest Takeda Pharmaceutical seller in Q4 2022 was Brandes Investment Partners, an estimated $24.5M sold.
Based on aggregated 13F filings for Q4 2022.